Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461
Completed · Phase 1 · NCT02329184
Conditions: Hypertrophic Cardiomyopathy
At a glance
- Research payments reported, 2025
- $915,244
- U.S. investigators named
- 23
- Sites paid
- 21
- Planned or actual enrollment
- 15
About the trial
- Sponsor
- MyoKardia, Inc.
- Tested
- MYK-461 (drug)
- Dates
- Started 2014-12; completion 2016-04
- Results posted
- Not yet
The purpose of this study is to establish initial safety, tolerability, pharmacokinetics and pharmacodynamics of MYK-461 in human subjects. This is a sequential group, single ascending (oral) dose study in NYHA Class I, II, or III patient volunteers aged 18-65 years.
From ClinicalTrials.gov, last updated 2016-09-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $915,244 in research payments for this study in 2025 (22 payments).
Products named: Camzyos
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Said Alsidawi, M.D. Cardiology · Scottsdale, AZ
- Theodore P. Abraham, M.D. Cardiology · San Francisco, CA
- Florian Rader, MD Cardiology · West Hollywood, CA
- Matthew T. Wheeler, MD Heart Failure & Transplant Cardiology · Stanford, CA
- John Stendahl Cardiology · New Haven, CT
- Neal K. Lakdawala, MD Cardiology · Boston, MA
- Alan P. Jacobsen, MB BCH BAO Interventional Cardiology · Baltimore, MD
- David R. Fermin, M.D. Heart Failure & Transplant Cardiology · Grand Rapids, MI
- Sara Saberi, MD Cardiology · Ann Arbor, MI
- Alan R. Warren, DPM Podiatrists · St Clair Shores, MI
- Shuktika Nandkeolyar, MD Heart Failure & Transplant Cardiology · Charlotte, NC
- Andrew Wang, M.D. Cardiology · Durham, NC
- Mathew S. Maurer, M.D. Heart Failure & Transplant Cardiology · New York, NY
- Mark V. Sherrid, M.D. Cardiology · New York, NY
- Anjali T. Owens, MD Heart Failure & Transplant Cardiology · Philadelphia, PA
- Jamshid Shirani, M.D. Cardiology · Bethlehem, PA
- Timothy C. Wong, M.D. Cardiology · Pittsburgh, PA
- Isaac B. Rhea, M.D. Cardiology · Memphis, TN
- Sherif Nagueh, M.D. Cardiology · Houston, TX
- Ernesto A. Ruiz Duque, MD Heart Failure & Transplant Cardiology · Temple, TX
- Kia Afshar, M.D. Internal Medicine · Murray, UT
- James P. Macnamara, M.D. Cardiology · Charlottesville, VA
- David S. Owens, MD Cardiology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Cedars-Sinai Medical Center, CA $134,015
- University of Michigan Health System, MI $120,802
- Duke University (416) $74,795
- University of Washington Medical Ctr, WA $74,685
- Stanford University Board of Trustees $72,051
- University of Utah Hospital and Clinics, UT $67,051
- Mayo Clinic Hospital, AZ $63,014
- Hospital of Univ of Pennsylvania, PA $46,593
- Houston Methodist Research Institute $36,264
- Intermountain Medical Center, UT $35,089
- NYU School of Medicine $32,190
- Brigham and Women's Hospital, MA $26,818
- The Trustees of Columbia University in The City of New York $21,853
- Carolinas Medical Center-Northeast, NC $20,286
- Spectrum Health Hospitals $16,441
- St Lukes Hospital, PA $16,278
- University of Pittsburgh Physicians $15,479
- Lee Daeyeol Mms $15,029
- Methodist Healthcare Foundation $10,358
- University of Texas Southwestern $9,494
- University of Iowa Hospital & Clinics, IA $6,659
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.